Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines

Molecular Carcinogenesis

Volumn 50, Issue 3, 2011, Pages 173-183

  DiNatale, Brett C ^a   Schroeder, Jennifer C ^a   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

AHR; Antagonist; Aryl hydrocarbon receptor; Cytokines; IL6

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; BRG1 PROTEIN; COREPRESSOR PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; RECEPTOR BLOCKING AGENT;

ARTICLE; CANCER CELL CULTURE; CYTOKINE PRODUCTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRACHLORODIBENZODIOXIN; TUMOR CELLS, CULTURED;

EID: 79951826309     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20702     Document Type: Article

References (55)

1. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 2008; 18: 207-250.
2. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008; 105: 9721-9726.
3. Patel RD, Murray IA, Flaveny CA, Kusnadi A, Perdew GH. Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest 2009; 89: 695-707.
4. Kharat I, Saatcioglu F. Antiestrogenic effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem 1996; 271: 10533-10537.
5. Furness SG, Whelan F. The pleiotropy of dioxin toxicity-xenobiotic misappropriation of the aryl hydrocarbon receptor's alternative physiological roles. Pharmacol Ther 2009; 124: 336-353.
6. Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia 2000; 5: 295-306.
7. Vogel CF, Matsumura F. A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family. Biochem Pharmacol 2009; 77: 734-745.
8. Wang SH, Liang CT, Liu YW, et al. Crosstalk between activated forms of the aryl hydrocarbon receptor and glucocorticoid receptor. Toxicology 2009; 262: 87-97.
9. Kawajiri K, Kobayashi Y, Ohtake F, et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci USA 2009; 106: 13481-13486.
10. Hollingshead BD, Beischlag TV, DiNatale BC, Ramadoss P, Perdew GH. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Res 2008; 68: 3609-3617.
11. DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH. Mechanistic insights into the events that lead to synergistic induction of IL6 transcription upon activation of the Ah receptor and inflammatory signaling. J Biol Chem 2010; 285: 24388-24397.
12. Cavarretta IT, Neuwirt H, Untergasser G, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007; 26: 2822-2832.
13. Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61: 8851-8858.
14. Asgeirsson KS, Olafsdóttir K, Jónasson JG, Ogmundsdóttir HM. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 1998; 10: 720-728.
15. Badache A, Hynes NE. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 2001; 61: 383-391.
16. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer. FASEB J 2007; 21: 3763-3770.
17. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988-4002.
18. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1369-1379.
19. Pries R, Thiel A, Brocks C, Wollenberg B. Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 2006; 20: 45-48.
20. Woods KV, El-Naggar A, Clayman GL, Grimm EA. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 1998; 58: 3132-3141.
21. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113: 750-757.
22. Tong M, Lloyd B, Pei P, Mallery SR. Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem 2008; 105: 1202-1210.
23. Rinaldi AL, Morse MA, Fields HW, et al. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7, 8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res 2002; 62: 5451-5456.
24. Yeudall WA, Crawford RY, Ensley JF, Robbins KC. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994; 15: 2683-2686.
25. Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007; 9: R15.
26. Murray IA, Flaveny CA, DiNatale BC, et al. Antagonism of aryl hydrocarbon receptor signaling by 6, 2', 4'-trimethoxyflavone. J Pharmacol Exp Ther 2010; 332: 135-144.
27. Wang S, Hankinson O. Functional involvement of the Brahma/SWI2-related gene 1 protein in cytochrome P4501A1 transcription mediated by the aryl hydrocarbon receptor complex. J Biol Chem 2002; 277: 11821-11827.
28. Taylor RT, Wang F, Hsu EL, Hankinson O. Roles of coactivator proteins in dioxin induction of CYP1A1 and CYP1B1 in human breast cancer cells. Toxicol Sci 2009; 107: 1-8.
29. Trotter KW, Archer TK. The BRG1 transcriptional coregulator. Nucl Recept Signal 2008; 6: e004.
30. Ni Z, Karaskov E, Yu T, et al. Apical role for BRG1 in cytokine-induced promoter assembly. Proc Natl Acad Sci USA 2005; 102: 14611-14616.
31. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: A perspective on potential roles in the immune system. Immunology 2009; 127: 299-311.
32. van Grevenynghe J, Rion S, Le Ferrec E, et al. Polycyclic aromatic hydrocarbons inhibit differentiation of human monocytes into macrophages. J Immunol 2003; 170: 2374-2381.
33. Dietrich C, Kaina B. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 2010; 8: 1319-1328.
34. Ishida M, Mikami S, Kikuchi E, et al. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 2010; 31: 287-295.
35. Chiaro CR, Morales JL, Prabhu KS, Perdew GH. Leukotriene A4 metabolites are endogenous ligands for the Ah receptor. Biochemistry 2008; 47: 8445-8455.
36. Chiaro CR, Patel RD, Perdew GH. 12(R)-Hydroxy-5(Z), 8(Z), 10(E), 14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor. Mol Pharmacol 2008; 74: 1649-1656.
37. DiNatale BC, Murray IA, Schroeder JC, et al. Kynurenic acid is a potent endogenous Ah receptor ligand that synergistically induces interleukin 6 in the presence of inflammatory signaling. Toxicol Sci 2010; 115: 89-97.
38. Schroeder JC, DiNatale BC, Murray IA, et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010; 49: 393-400.
39. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003; 63: 2948-2956.
40. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006; 119: 1268-1275.
41. Leeman-Neill RJ, Wheeler SE, Singh SV, et al. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009; 30: 1848-1856.
42. Gu F, Ma Y, Zhang Z, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010; 23: 671-676.
43. Kondo N, Tsukuda M, Ishiguro Y, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010; 23: 957-963.
44. Al-Sarraf M. Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control 2002; 9: 387-399.
45. Bui LC, Tomkiewicz C, Chevallier A, et al. Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene 2009; 28: 3642-3651.
46. Hashimoto Y, Loftis DW, Adams JC. Fascin-1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells. PLoS One 2009; 4: e5130.
47. Carvajal-Gonzalez JM, Mulero-Navarro S, Roman AC, et al. The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion. Mol Biol Cell 2009; 20: 1715-1727.
48. Miller ME, Holloway AC, Foster WG. Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output. Clin Exp Metastasis 2005; 22: 149-156.
49. Weiss C, Faust D, Schreck I, et al. TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A. Oncogene 2008; 27: 2198-2207.
50. Peng TL, Chen J, Mao W, Song X, Chen MH. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol 2009; 10: 27.
51. Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE. The selective aryl hydrocarbon receptor modulator 6-methyl-1, 3, 8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 2009; 77: 1151-1160.
52. Zhang S, Lei P, Liu X, et al. The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr Relat Cancer 2009; 16: 835-844.
53. Murray IA, Krishnegowda G, DiNatale BC, et al. Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem Res Toxicol 2010; 23: 955-966.
54. Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993; 328: 159-163.
55. Zevallos JP, Mallen MJ, Lam CY, et al. Complications of radiotherapy in laryngopharyngeal cancer: Effects of a prospective smoking cessation program. Cancer 2009; 115: 4636-4644.